AN experimental drug from Eli Lilly works best if Alzheimer's patients are treated as early as possible, ideally before they develop symptoms of the brain-wasting disease, researchers said on Monday, in the latest promising development for treating the most common form of dementia.
The drug, donanemab, has been shown to slow progression of memory and thinking problems by about a third, but that rate doubles to 60% if the drug is started when patients are only mildly impaired, according to new trial data presented at the Alzheimer's Association International Conference in Amsterdam.
The full analysis from the study involving more than 1,700 patients showed that results were less robust for older, later-stage patients as well as those with higher levels of a protein called tau that has been linked to Alzheimer's disease progression.
The findings underscore that "earlier detection and diagnosis can really change the trajectory of this disease," said Anne White, president of neuroscience at Lilly.
Lilly expects the U.S. Food and Drug Administration to decide by the end of this year whether to approve donanemab. It said submissions to other global regulators are underway, and most will be completed by year end.
Donanemab, like the recently approved Leqembi from Eisai 4523.T and Biogen BIIB.O, is an intravenous antibody designed to remove deposits of a protein called beta amyloid from the brains of Alzheimer's patients.
Referring to Lilly's data released on Monday, Dr. Susan Kohlhaas, executive director of research & partnerships at Alzheimer's Research UK, said, "These results provide further confirmation that removing amyloid from the brain can change the course of Alzheimer's, and may help people affected by this devastating disease if they're treated at the right time."
SIDE EFFECTS
Lilly's study showed that brain swelling, a known side effect of amyloid-clearing antibodies, occurred in more than 40% of patients with a genetic predisposition to develop Alzheimer's.
The company had previously reported that 24% of the overall donanemab treatment group had brain swelling. Brain bleeding occurred in 31% of the donanemab group and about 14% of the placebo group.
The deaths of three trial patients were linked to the treatment, researchers reported.
"These side effects should not be taken lightly," but most cases were manageable by monitoring with magnetic resonance imaging (MRI) or stopping the drug, said study investigator Dr. Liana Apostolova, professor in Alzheimer's Disease research at Indiana University School of Medicine.
Doctors are likely to use "very stringent MRI safety screening while we treat these patients," she said.
Lilly said donanemab's treatment effect continued to increase relative to placebo over the course of the 18-month trial, even for participants who had been taken off the drug after their levels of amyloid deposits fell significantly.
"At the end of the trial, the average patient had been without drug for seven months and yet they continued to benefit," White said.
She said the findings support the idea that donanemab can be stopped once amyloid is cleared from the brain.
"Some patients did not worsen significantly during the trial and on average progression of disease was slowed 4.4-7.5 months over 18 months," said Dr. Liz Coulthard, associate professor in dementia neurology at the University of Bristol.
Lilly said in May that the study had met all of its goals, showing that donanemab slowed cognitive decline by 29% compared to a placebo in people with mild cognitive impairment or mild dementia whose brains had deposits of two key Alzheimer's proteins, beta amyloid and tau.
For high tau patients, donanemab was shown to slow disease progression by about 17%, while the benefit was 35% for those with low-to-intermediate tau levels.
The full study results were also published in JAMA.
"Whether the harms of these drugs are balanced by their modest clinical benefits will ultimately require more data," an editorial in JAMA alongside the study said.
The FDA this month granted standard approval to Leqembi, the first Alzheimer's disease-modifying treatment to achieve that goal, clearing the way for wider insurance coverage of the drug.
Both medications are also being studied in large trials to see if they have an impact on delaying onset of Alzheimer's disease symptoms.
The latest study "gives me great hope" for the outcomes of those prevention trials, said Dr. Reisa Sperling, who directs the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital in Boston.
More than 6 million Americans are living with Alzheimer's, according to the Alzheimer's Association. More than 55 million people worldwide have Alzheimer's or other forms of dementia, according to the U.N. World Health Organization.
Shares of Lilly, which reached an all-time high near $469 in June, were nearly unchanged at $449.98 in midday trading on the New York Stock Exchange.
Reuters
Tue Jul 18 2023

The drug, donanemab, has been shown to slow progression of memory and thinking problems by about a third, but that rate doubles to 60% if the drug is started when patients are only mildly impaired, according to new trial data presented. - UNSPLASH

Sabah has allocated over RM75 million for education aid initiatives - Hajiji
Sabah has allocated RM75.5 million this year to implement 13 education aid initiatives for students, schools, parent-teacher associations, as well as Sabah student associations

Ismail Sabri will continue providing statement tomorrow - Azam
MACC chief commissioner Tan Sri Azam Baki has confirmed that former PM Datuk Seri Ismail Sabri Yaakob will return tomorrow morning to continue providing his statement

PM Anwar wants faster implementation of rural infrastructure projects
Datuk Seri Anwar Ibrahim today directed the Rural and Regional Development Ministry (KKDW) to expedite basic infrastructure projects that are crucial for the well-being of the people.

Russia lays out demands for talks with US on Ukraine, sources say
Russia has presented the U.S. with a list of demands for a deal to end its war against Ukraine and reset relations with the US, sources say

Astro launches Max on the Ultra and Ulti Box, bringing more premium entertainment options to Malaysian homes
Astro, Malaysias leading content and entertainment provider, today announced that Max, the premier streaming service from Warner Bros.

Duterte takes responsibility for Philippines drug war, anticipates long ICC battle
Former Philippine President Rodrigo Duterte said he takes full responsibility for his administration's "war on drugs"

Canada announces plan to ease Syria sanctions
The Canadian government on Wednesday announced plans to ease sanctions on Syria during what it called a period of transition.

Zii Jia pulls out of Swiss Open due to injury
Malaysia's men's singles shuttler Lee Zii Jia has withdrawn from next week's Swiss Open due to a recurring right ankle injury.

MCMC probes man for uploading fake content on social media
A 47-year-old Malaysian man is being investigated for allegedly uploading fake content that touches on the 3R (religion, race and royalty) on social media.

KPDN calls on public to help report bottled cooking oil shortage
The Ministry of Domestic Trade and Cost of Living (KPDN) has urged the public to be the eyes and ears of the ministry and report shortages of bottled cooking oil in their areas.

ICJ to hold public hearings on Israel's obligations in occupied Palestinian territory
The International Court of Justice will hold hearings next month on Israel's obligations towards Palestinians, Anadolu Ajansi (AA) reported.

Anwar: Sapura Energy's rescue plan excludes former shareholders
Prime Minister Datuk Seri Anwar Ibrahim said Sapura Energy Bhd's (SEB) former major shareholders are no longer involved in the company's management as part of its restructuring efforts.

Intel names Lip-Bu Tan as new CEO
Intel Corporation (INTC.O) has appointed semiconductor Malaysian-born industry veteran and former board member Lip-Bu Tan as its new CEO.

Ismail Sabri at MACC HQ to give statement
Former Prime Minister Datuk Seri Ismail Sabri Yaakob was at the Malaysian Anti-Corruption Commission (MACC) headquarters here today to give his statement

Duterte could face up to 30 years or life imprisonment if convicted by ICC - Malacanang
Former Philippines President Rodrigo Duterte could face up to 30 years or life imprisonment if convicted of crimes against humanity by the International Criminal Court (ICC)

Clarification on the investment in Sapura Energy by MDH
Permodalan Nasional Berhad (PNB) as the existing significant shareholder of SEB.

Floods recede in Beaufort, but residents remain wary of downstream water flow
While floods in Beaufort are receding, residents remain on alert for downstream water flow that could bring floodwaters from inland areas.

Govt to ensure establishment of SEGiM aligns with introduction of Gig Workers Bill
The government intends to ensure that the establishment of the Malaysian Gig Economy Commission (SEGiM) is in line with the introduction of the Gig Workers Bill.

UK steel industry warns of damage as Trump tariffs come into force
US President Donald Trump's tariffs on UK steel "couldn't come at a worse time," the industry has warned as the levy on US imports is introduced, reported PA Media/dpa news.

Penang allocates RM49.45 million for Phase 1 of i-Sejahtera Programme
The Penang government has allocated RM49.45 million for 274,151 recipients under Phase 1 of the i-Sejahtera Programme this year.